HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhu, Y. Z. Articles by Lee, H. S. Search for Related Content PubMed Articles by Zhu, Y. Z. Articles by Lee, H. S.

Angiotensin-Converting Enzyme Inhibition After Myocardial Infarction

Department of Pharmacology Faculty of Medicine National University of Singapore Singapore, Republic of Singapore

For reprint information contact: Zhu Yi Zhun, MD Tel: 65 874 3676 Fax: 65 773 0579 email: phczhuyz{at}nus.edu.sg, Department of Pharmacology, Faculty of Medicine, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260, Republic of Singapore.

Myocardial infarction was the underlying event in the majority of deaths from cardiovascular disease in Western countries in the past quarter-century. The introduction of angiotensin-converting enzyme inhibitors to the treatment of heart failure following myocardial infarction was a major advance in the last 10 years. However, the role of cardiac angiotensin-converting enzyme during postinfarction cardiac remodeling remains to be elucidated. Experimental studies demonstrated that angiotensin-converting enzyme inhibitors administered one week before myocardial infarction could limit infarct size, improve cardiac function, and prevent cardiac hypertrophy. Numerous large-scale clinical trials have shown that angiotensin-converting enzyme inhibitors are safe and can reduce mortality and the occurrence of severe left ventricular dysfunction after myocardial infarction. This review focuses on the effects of these inhibitors in experimental studies and in multicenter clinical trials.

This article has been cited by other articles:

				A. E Berezin Losartan in the Therapy of Heart Failure Patients Asian Cardiovasc Thorac Ann, December 1, 2001; 9(4): 302 - 307. [Abstract] [Full Text] [PDF]